Mesoblast partners with blood and marrow transplant clinical trials network (bmt ctn) on pivotal trial in adults with sr-agvhd

New york, nov. 21, 2023 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the blood and marrow transplant clinical trials network (bmt ctn), a body including centers responsible for approximately 80% of all us allogeneic bmts, has entered into an agreement to develop a pivotal trial of mesoblast's lead product candidate ryoncil® (remestemcel-l) in the treatment of adults with steroid-refractory acute graft versus host disease (sr-agvhd). the bmt ctn is funded by the united states national institutes of health (nih).
MESO Ratings Summary
MESO Quant Ranking